Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial

Tuesday, UCB SA (OTC:UCBJY) (OTC:UCBJF) and Biogen Inc. (NASDAQ:BIIB) released topline results from the Phase 3 PHOENYCS GO study of dapirolizumab pegol for moderate-to-severe systemic lupus erythematosus (SLE). SLE is a chronic autoimmune disease that can affect many organs in the body. It occurs when the body’s immune system attacks healthy tissue, causing inflammation and sometimes permanent tissue damage. SLE can present itself in several ways, including rash, arthritis, anemia, thrombocytopenia, serositis, nephritis, seizures or ...